Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome
Improved Hepascore in hepatitis C predicts reversal in risk of adverse outcome作者机构：School of Medicine University of Notre Dame School of Medicine and Pharmacology University of Western Australia Department of Hepatology Sir Charles Gairdner Hospital Department of Anatomical Pathology Path West QEII Medical Centre Department of Microbiology Path West QEII Medical Centre Department of Biochemistry Path West QEII Medical Centre
出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)
年 卷 期：2017年第9卷第19期
页 面：850-856页
学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 100401[医学-流行病与卫生统计学] 10[医学]
主 题：Chronic Prognosis Direct acting antivirals Serum Hepatitis C
摘 要：AIM To establish if serial Hepascore tests(referred to as delta Hepascore) in those with chronic hepatitis C(CHC) correlate with the increase and/or decrease in risk of liver related *** Three hundred and forty-six CHC patients who had two Hepascore tests performed were studied. During 1944 patient years follow-up 28(8.1%) reached an endpoint. The Hepascore is a serum test that provides clinically useful data regarding the stage of liver fibrosis andsubsequent clinical outcomes in chronic liver *** Patients with a baseline Hepascore 0.75 had a significantly increased rate of reaching a composite endpoint consisting of hepatocellular carcinoma, liver death, and/or decompensation(P 0.75, a subsequent improved Hepascore showed a significantly decreased risk for the composite endpoint(P = 0.004). There were no negative outcomes in those with a stable or improved delta Hepascore. The minimum time between tests that was found to give a statically significant result was in those greater than one year(P = 0.03).CONCLUSION In conclusion, Hepascore is an accurate predictor of liver related mortality and liver related morbidity in CHC patients. Of note, we have found that there is a decreased risk of mortality and morbidity in CHC patients when the patient has an improving delta Hepascore. Repeat Hepascore tests, when performed at a minimum one-year interval, may be of value in routine clinical practice to predict liver related clinical outcomes and to guide patient management.
维普期刊数据库